## Rallis India

## Performance Highlights

| Y/E March (₹ cr) | 3QFY2016 | 2QFY2016 | \% chg (q०q) | 3QFY2015 | \% chg (yoy) |
| :--- | ---: | ---: | ---: | ---: | ---: |
| Net sales | 306 | 500 | $(38.7)$ | 385 | $(20.4)$ |
| Other income | 5 | 5 | 1.5 | 6 | $(18.7)$ |
| Gross profit | 148 | 233 | $(36.7)$ | 180 | $(18.0)$ |
| Operating profit | 31 | 95 | $(67.1)$ | 46 | $(32.4)$ |
| Adj. Net profit | 20 | 57 | $(64.4)$ | 25 | $(19.9)$ |

Source: Company, Angel Research
Rallis India (Rallis) posted a disappointing set of numbers for 3QFY2016. Sales for the quarter came in at ₹306cr V/s ₹385cr in 3QFY2015, a dip of $20.4 \%$ yoy. Higher sales return in the domestic segment and cancellation of orders by clients in global markets, along with a dip in the seed business, led to the decline in the top-line. On the operating front, the gross margin came in at $48.2 \%$ $\mathrm{V} / \mathrm{s} 46.8 \%$ in 3QFY2015; still the OPM declined to $10.2 \% \mathrm{~V} / \mathrm{s} 12.0 \%$ in 3QFY2015. This was owing to lower sales during the quarter. The PAT came in at ₹ $20 \mathrm{cr} \mathrm{V} / \mathrm{s}$ ₹ 25 cr in 3QFY2015, a dip of $19.9 \%$ yoy. We remain Neutral on the stock.

Disappointing numbers for the quarter: Sales for the quarter came in at ₹ 306 cr V/s ₹385cr in 3QFY2015, a dip of $20.4 \%$ yoy. Higher sales return in the domestic segment and cancellation of orders by clients in global markets, along with a dip in the seed business, led to the decline in the top-line. On the operating front, the gross margin came in at $48.2 \% \mathrm{~V} / \mathrm{s} 46.8 \%$ in 3QFY2015; still the OPM declined to $10.2 \% \mathrm{~V} / \mathrm{s} 12.0 \%$ in 3QFY2015. This was owing to lower sales during the quarter. The PAT came in at ₹ $20 \mathrm{cr} \mathrm{V} / \mathrm{s}$ ₹ 25 cr in 3QFY2015, a dip of $19.9 \%$ yoy. The dip in PAT was lower than that in the EBDITA as tax outgo during the quarter was lower than in the corresponding quarter of last year.

Outlook and valuation: Given the pressure on the financials, we expect Rallis to register an $8.9 \%$ dip in sales in FY2016. For FY2015-17E, we expect a CAGR of $3.7 \%$ and $3.4 \%$ in net sales and profit, respectively, with recovery expected in FY2017E. At the current levels, the stock is trading at a fair valuation of $17.3 x$ its FY2017E EPS. Hence, we maintain our Neutral recommendation on the stock.

Key financials (Consolidated)

| Y/E March (₹ cr) | FY2014 | FY2015 | FY2016E | FY2017E |
| :--- | ---: | ---: | ---: | ---: |
| Net Sales | 1,747 | 1,822 | 1,660 | 1,960 |
| \% chg | 19.8 | 4.3 | $(8.9)$ | 18.0 |
| Adj.Net Profit | 152 | 157 | 140 | 168 |
| \% chg | 32.9 | 3.5 | $(11.0)$ | 20.2 |
| EBITDA \% | 13.9 | 14.2 | 14.4 | 14.4 |
| FDEPS (₹) | 7.8 | 8.1 | 7.2 | 8.6 |
| P/E (x) | 19.2 | 18.5 | 20.8 | 17.3 |
| P/BV (x) | 4.1 | 3.6 | 3.3 | 3.0 |
| RoE (\%) | 22.7 | 20.5 | 16.5 | 18.0 |
| RoACE (\%) | 26.4 | 24.7 | 20.1 | 22.3 |
| EV/Sales (x) | 2.4 | 2.3 | 2.5 | 2.1 |
| EV/EBITDA $(x)$ | 17.4 | 16.4 | 17.6 | 14.8 |


| NEUTRAL |  |
| :--- | ---: |
| CMP |  |
| Target Price | ₹150 |
| Investment Period | - |
|  | - |
| Stock Info | Agrichemical |
| Sector | 2,908 |
| Market Cap (₹ cr) | 126 |
| Net debt (₹ cr) | 0.9 |
| Beta | $299 / 143$ |
| 52 Week High / Low | 84,191 |
| Avg. Daily Volume | 1 |
| Face Value (₹) | 24,480 |
| BSE Sensex | 7,435 |
| Nifty | RALL.BO |
| Reuters Code | RALI@IN |
| Bloomberg Code |  |


| Shareholding Pattern (\%) |  |
| :--- | :--- |
| Promoters | 50.1 |
| MF / Banks / Indian Fls | 14.5 |
| FII / NRIs / OCBs | 13.6 |
| Indian Public / Others | 21.8 |


| Abs. (\%) | 3 m | lyr | $3 y \mathrm{r}$ |
| :--- | ---: | ---: | ---: |
| Sensex | $(10.5)$ | $(13.4)$ | 22.2 |
| Rallis India | $(30.1)$ | $(33.3)$ | 2.2 |

3-year price chart


Source: Company, Angel Research

Sarabjit Kour Nangra
+91-22-39357800 ext. 6806
sarabjii@angelbroking.com

[^0]Exhibit 1: 3QFY2016 performance (Consolidated)

| Y/E March (₹ cr) | 3QFY2016 | 2QFY2016 | \% chg (q०q) | 3QFY2015 | \% chg (yoy) | 9 MFY 2016 | 9MFY2015 | \% chg |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Net sales | 306 | 500 | (38.7) | 385 | (20.4) | 1,270 | 1,486 | (14.6) |
| Other income | 5 | 5 | 1.5 | 6 | (18.7) | 15 | 17 | (12.3) |
| Total income | 311 | 505 | (38.3) | 391 | (20.4) | 1,284 | 1,503 | (14.5) |
| Gross profit | 148 | 233 | (36.7) | 180 | (18.0) | 625 | 660 | (5.3) |
| Gross margin (\%) | 48.2 | 46.7 |  | 46.8 |  | 49.2 | 44.4 |  |
| EBDITA | 31 | 95 | (67.1) | 46 | (32.4) | 178 | 219 | (18.6) |
| EBDITA margin (\%) | 10.2 | 18.9 |  | 12.0 |  | 14.0 | 14.7 |  |
| Financial cost | 4 | 3 | 27.4 | 3 | 21.0 | 11 | 8 | 32.1 |
| Depreciation | 14 | 13 | 7.5 | 13 | 7.5 | 39 | 36 | 7.5 |
| PBT | 18 | 84 | (78.0) | 36 | (49.0) | 144 | 192 | (25.1) |
| Provision for taxation | 0 | 28 | (101.4) | 13 | (103.1) | 29 | 53 | (44.8) |
| PAT Before Exc. And MI | 19 | 56 | (66.4) | 23 | (18.4) | 115 | 139 | (17.5) |
| Minority | (2) | (1) |  | (2) |  | 4 | 3 | - |
| Exceptional | 0 | 0 |  | 0 |  | 0 | 0 |  |
| Reported PAT | 20 | 57 | (64.4) | 25 | (19.9) | 111 | 136 | (18.5) |
| Adjusted PAT | 20 | 57 | (64.4) | 25 | (19.9) | 111 | 136 | (18.5) |
| EPS (F) | 1.0 | 2.9 |  | 1.3 |  | 5.7 | 7.0 |  |

Source: Company, Angel Research

## Sales decline by 20.4\% yoy

Sales for the quarter came in at ₹ 306 cr V/s ₹385cr in 3QFY2015, a dip of 20.4\% yoy. Higher sales return in the domestic segment and cancellation of orders by clients in global markets, along with a dip in the seed business, led to the decline in the top-line. The seed business posted a $17 \%$ yoy decline for the quarter to $₹ 29 \mathrm{cr}$ against our estimate of ₹ 36.5 cr in a seasonally short quarter for seeds. The company's domestic agrochemical business saw weak demand during the shortened rabi season as low ground water level and extension of kharif season into rabi reduced the sowing window available to farmers. Consequently, channel inventory remained high, thereby forcing the company to take back inventory from the system. As a result, sales return remained high during the quarter.

Exhibit 2: Total revenue performance


[^1]
## OPM dips yoy

On the operating front, the gross margin came in at $48.2 \% \mathrm{~V} / \mathrm{s} 46.8 \%$ in 3QFY2015, inspite of which the OPM dipped to $10.2 \% \mathrm{~V} / \mathrm{s} 12.0 \%$ in 3QFY2015, mainly on lower sales. A $6.0 \%$ and $15.7 \%$ yoy rise in staff costs and other expenditure, respectively, weighed down margins.

Exhibit 3: Margin trend (\%)


Source: Company, Angel Research

## Earnings decline

The PBT for the quarter posted a decline of $49.0 \%$ yoy owing to an $18.7 \%$ dip in other income. The Adj. net profit declined by $19.9 \%$ yoy to $\sim$ ₹ 20 cr . There was a tax credit during the quarter of $₹ 0.4 \mathrm{cr} \mathrm{V} / \mathrm{s}$ tax outgo of $₹ 25 \mathrm{cr}$ in 3 QFY 2015.

Exhibit 4: Adjusted PAT trend


[^2]
## Concall highlights

- The company's domestic agrochemical business saw weak demand during the shortened rabi season as low ground water level and extension of kharif season into rabi reduced the sowing window available to farmers. Consequently, channel inventory remained high, thereby forcing the company to take back inventory from the system. As a result, sales return remained high during the quarter.
- The company's export business saw the adverse impact of global slowdown for the second straight quarter. Tough operating environment in key geographies such as Brazil and USA have led to many orders getting differed or even cancelled. Exports account for 30-33\% of Rallis' total revenues. The Management expects some of the orders lost during 1 HFY2016 to come back in 4QFY2016.


## Investment arguments

Company set to seize rising opportunities in the domestic crop protection market: India's overall pesticide consumption is one of the lowest in the world, and has a huge potential to grow. We believe Rallis is well placed to seize this opportunity on the back of its wide distribution network, strong brands, and a robust new-product pipeline. According to industry estimates, the unorganized market accounts for $50 \%$ of the industry. Nonetheless, we believe Rallis is in a position to wrest market share as well as charge a premium for its products. Further, the company has enhanced focus on the non-pesticide side of the business, which is a high growth segment, and now constitutes around $30 \%$ of its overall sales. On back of a weaker FY2016, we expect the company to post a dip in domestic sales, which should bounce back in FY2017E.

Exports to register steady growth: Although a late entrant, the company has been enhancing its focus in the exports market, which is now turning out to be its main growth driver. Overall exports formed $\sim 30 \%$ of sales in FY2015. Going forward, the segment will continue to post a $20 \%$ CAGR over FY2015-17E.

Contract manufacturing to be the next growth driver: Rallis plans to focus on contract manufacturing for exports and selectively target top players. To facilitate the same, the company has set up a plant at Dahej, which in FY2013 was working at full capacity and contributed significantly to the overall growth of the company. Overall, Rallis targets to achieve a cumulative revenue of $₹ 1,000 \mathrm{cr}$ over the next five years from this segment alone.

## Outlook and valuation

Given the pressure on the financials, we expect Rallis to register an $8.9 \%$ dip in sales in FY2016. For FY2015-17E, we expect a CAGR of $3.7 \%$ and $3.4 \%$ in net sales and profit, respectively, with recovery expected in FY2017E. At the current levels, the stock is trading at a fair valuation of $17.3 x$ its FY2017E EPS. Hence, we maintain our Neutral recommendation on the stock.

Exhibit 5: Key assumptions

| Particulars (\%) | FY2016E | FY2017E |
| :--- | ---: | ---: |
| Domestic growth | $(20.0)$ | 13.0 |
| Export growth | $(16.7)$ | 28.0 |
| Total revenue growth | $(8.9)$ | 18.0 |
| EBITDA margin | 14.4 | 14.4 |
| Capex (₹ cr) | 50 | 70 |

Source: Company, Angel Research

Exhibit 6: Peer valuation

| Company | Reco | Mcap <br> (₹ cr) | CMP <br> (₹) | $\begin{aligned} & \text { TP } \\ & \text { (₹) } \\ & \hline \end{aligned}$ | Upside(\%) | P/E (x) |  | EV/Sales (x) |  | EV/EBITDA (x) |  | RoE (\%) |  | CAGR (\%) |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  |  |  | FY16E | FY17E | FY16E | FY17E | FY16E | FY17E | FY16E | FY17E | Sales | PAT |
| Rallis | Neutral | 2,908 | 149 | - | - | 20.8 | 17.3 | 2.5 | 2.1 | 17.6 | 14.8 | 16.5 | 18.0 | 3.7 | 3.4 |
| United Phosphorus | Buy | 13,698 | 392 | 510 | 30.1 | 12.2 | 10.2 | 1.3 | 1.1 | 7.5 | 6.2 | 21.4 | 21.3 | 15.0 | 20.0 |

Source: Company, Angel Research, Bloomberg

## Exhibit 7: One-year forward P/E band



Source: C-line, Angel Research

## Company background

Rallis is one of the oldest and second largest pesticide agrichemical companies in the country with a market share of around $13 \%$ and belongs to the Tata Group. The company also has a credible presence in the international market. Pesticides account for $97 \%$ of the company's total revenues, while plant nutrients, seeds and leather chemicals contribute the balance. Contribution from the domestic business stands at $\sim 70 \%$, while exports account for the balance.

Profit \& loss (Consolidated)

| Y/E March (₹ cr) | FY2012 | FY2013 | FY2014 | FY2015 | FY2016E | FY2017E |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Gross sales | 1,328 | 1,535 | 1,840 | 1,922 | 1,736 | 2,048 |
| Less: Excise duty | 79 | 95 | 114 | 121 | 97 | 109 |
| Net Sales | 1,249 | 1,440 | 1,726 | 1,801 | 1,639 | 1,939 |
| Other operating income | 25 | 18 | 21 | 21 | 21 | 21 |
| Total operating income | 1,275 | 1,458 | 1,747 | 1,822 | 1,660 | 1,960 |
| \% chg | 17.4 | 14.4 | 19.8 | 4.3 | (8.9) | 18.0 |
| Total Expenditure | 1,058 | 1,241 | 1,485 | 1,545 | 1,404 | 1,660 |
| Net Raw Materials | 695 | 823 | 1,008 | 995 | 952 | 1,126 |
| Other Mfg costs | 255 | 304 | 342 | 341 | 311 | 367 |
| Personnel | 90 | 94 | 111 | 129 | 118 | 139 |
| Other | 18 | 20 | 24 | 25 | 23 | 27 |
| EBITDA | 192 | 199 | 240 | 256 | 236 | 279 |
| \% chg | 10.0 | 3.9 | 20.8 | 6.5 | (8.0) | 18.3 |
| (\% of Net Sales) | 15.3 | 13.8 | 13.9 | 14.2 | 14.4 | 14.4 |
| Depreciation \& Amortisation | 29 | 32 | 41 | 50 | 50 | 54 |
| EBIT | 188 | 186 | 221 | 228 | 207 | 246 |
| \% chg | 6.3 | (1.5) | 18.9 | 3.1 | (9.1) | 18.8 |
| (\% of Net Sales) | 15.1 | 12.9 | 12.8 | 12.6 | 12.6 | 12.7 |
| Interest \& other Charges | 17 | 21 | 13 | 10 | 11 | 10 |
| Other Income | 5 | 5 | 6 | 4 | 4 | 4 |
| (\% of PBT) | 3 | 3 | 3 | 2 | 2 | 2 |
| Share in profit of Associates | - | - | - | - | - |  |
| Recurring PBT | 176 | 170 | 214 | 222 | 200 | 240 |
| \% chg | (4.2) | (3.5) | 26.3 | 3.4 | (9.8) | 20.2 |
| Extraordinary Expense/(Inc.) | (23) | 3 | - | - | - |  |
| PBT (reported) | 153 | 172 | 214 | 222 | 200 | 240 |
| Tax | 49 | 53 | 62 | 62 | 60 | 72 |
| (\% of PBT) | 31.8 | 31.0 | 28.8 | 27.9 | 30.0 | 30.0 |
| Minority Interest | 2 | (0) | 0.8 | 2.6 | 2.6 | 2.6 |
| PAT (reported) | 99 | 119 | 152 | 157 | 140 | 168 |
| ADJ. PAT | 109 | 114 | 152 | 157 | 140 | 168 |
| \% chg | (13.3) | 4.6 | 32.9 | 3.5 | (11.0) | 20.2 |
| (\% of Net Sales) | 8.7 | 7.9 | 8.8 | 8.7 | 8.5 | 8.7 |
| Basic EPS (F) | 5.6 | 5.9 | 7.8 | 8.1 | 7.2 | 8.6 |
| Fully Diluted EPS (\%) | 5.6 | 5.9 | 7.8 | 8.1 | 7.2 | 8.6 |
| \% chg | (13.3) | 4.6 | 32.9 | 3.5 | (11.0) | 20.2 |


| Balance sheet (Consolidated) |  |  |  |  |  |  |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: |
| Y/E March (₹ cr) | FY2012 | FY2013 | FY2014 | FY2015 | FY2016E | FY2017E |
| SOURCES OF FUNDS |  |  |  |  |  |  |
| Equity Share Capital | 19 | 19 | 19 | 19 | 19 | 19 |
| Preference Capital | - | - | - | - | - | - |
| Reserves \& Surplus | 534 | 601 | 699 | 795 | 866 | 966 |
| Shareholders Funds | 553 | 621 | 718 | 815 | 886 | 986 |
| Minority Interest | 1 | 5 | 10 | 10 | 10 | 10 |
| Total Loans | 151 | 131 | 75 | 111 | 111 | 80 |
| Other Long Term Liabilities | 0 | 6 | 4 | 4 | 4 | 4 |
| Long Term provisions | 18 | 30 | 15 | 19 | 19 | 19 |
| Deferred Tax Liability | 13 | 28 | 32 | 36 | 36 | 36 |
| Total Liabilities | 736 | 821 | 853 | 993 | 1,069 | 1,137 |
| APPLICATION OF FUNDS |  |  |  |  |  |  |
| Gross Block | 551 | 581 | 651 | 687 | 737 | 807 |
| Less: Acc. Depreciation | 189 | 195 | 233 | 282 | 332 | 386 |
| Net Block | 362 | 386 | 418 | 405 | 405 | 421 |
| Capital Work-in-Progress | 60 | 35 | 21 | 21 | 21 | 21 |
| Goodwill | 155 | 169 | 186 | 196 | 196 | 196 |
| Investments | 23 | 20 | 25 | 24 | 24 | 24 |
| Long Term Loans and Adv. | 91 | 92 | 98 | 110 | 94 | 111 |
| Current Assets | 432 | 488 | 549 | 680 | 725 | 833 |
| Cash | 11 | 26 | 9 | 7 | 79 | 69 |
| Loans \& Advances | 45 | 28 | 40 | 28 | 59 | 70 |
| Other | 375 | 435 | 500 | 645 | 587 | 694 |
| Current liabilities | 387 | 368 | 445 | 443 | 396 | 469 |
| Net Current Assets | 45 | 120 | 104 | 237 | 329 | 364 |
| Mis. Exp. not written off | - | - | - | - | - | $-1,069$ |
| Total Assets | 736 | 821 | 853 | 993 | 1,137 |  |
|  |  |  |  |  |  |  |

## Cash flow statement (Consolidated)

| Y/E March (₹ cr) | FY2012 | FY2013 | FY2014 | FY2015 | FY2016E | FY2017E |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: |
| Profit before tax | 153 | 172 | 214 | 222 | 200 | 240 |
| Depreciation | 29 | 32 | 41 | 50 | 50 | 54 |
| (Inc)/Dec in Working Capital | $(28)$ | $(61)$ | $(7)$ | $(147)$ | $(3)$ | $(63)$ |
| Direct taxes paid | $(38)$ | $(53)$ | $(62)$ | $(62)$ | $(60)$ | $(72)$ |
| Cash Flow from Operations | 144 | 150 | 186 | 63 | 187 | 160 |
| (Inc.)/ Dec. in Fixed Assets | $(55)$ | $(5)$ | $(56)$ | $(36)$ | $(50)$ | $(70)$ |
| (Inc.)/ Dec. in Investments | 3 | 3 | $(5)$ | 1 | - | - |
| Inc./ (Dec.) in loans and adv. |  |  |  |  |  |  |
| Cash Flow from Investing | $(52)$ | $(2)$ | $(61)$ | $(35)$ | $(50)$ | $(70)$ |
| Issue of Equity | - | - | - | - | - | - |
| Inc./(Dec.) in loans | 35 | $(6)$ | $(73)$ | 40 | 0 | $(31)$ |
| Dividend Paid (Incl. Tax) | $(47)$ | $(50)$ | $(55)$ | $(68)$ | $(68)$ | $(68)$ |
| Others | $(82)$ | $(78)$ | $(14)$ | $(1)$ | - | - |
| Cash Flow from Financing | $(95)$ | $(134)$ | $(142)$ | $(29)$ | $(65)$ | $(100)$ |
| Inc./(Dec.) in Cash | $(3)$ | 15 | $(17)$ | $(2)$ | 72 | $(10)$ |
| Opening Cash balances | 15 | 11 | 26 | 9 | 7 | 79 |
| Closing Cash balances | 11 | 26 | 9 | 7 | 79 | 69 |

Key ratios

| Y/E March | FY2012 | FY2013 | FY2014 | FY2015 | FY2016E | FY2017E |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Valuation Ratio ( x ) |  |  |  |  |  |  |
| P/E (on FDEPS) | 26.6 | 25.5 | 19.2 | 18.5 | 20.8 | 17.3 |
| P/CEPS | 16.2 | 19.3 | 15.1 | 14.1 | 15.3 | 13.1 |
| P/BV | 5.3 | 4.7 | 4.1 | 3.6 | 3.3 | 3.0 |
| Dividend yield (\%) | 1.3 | 1.3 | 1.3 | 1.3 | 2.0 | 2.7 |
| EV/Sales | 3.4 | 2.9 | 2.4 | 2.3 | 2.5 | 2.1 |
| EV/EBITDA | 22.3 | 21.3 | 17.4 | 16.4 | 17.6 | 14.8 |
| EV / Total Assets | 5.8 | 5.2 | 4.9 | 4.2 | 3.9 | 3.6 |
| Per Share Data ( F ) |  |  |  |  |  |  |
| EPS (Basic) | 5.6 | 5.9 | 7.8 | 8.1 | 7.2 | 8.6 |
| EPS (fully diluted) | 5.6 | 5.9 | 7.8 | 8.1 | 7.2 | 8.6 |
| Cash EPS | 9.3 | 7.7 | 9.9 | 10.6 | 9.8 | 11.4 |
| DPS | 2.0 | 2.0 | 2.0 | 2.0 | 3.0 | 4.0 |
| Book Value | 28.4 | 31.9 | 36.9 | 41.9 | 45.6 | 50.7 |
| Dupont Analysis |  |  |  |  |  |  |
| EBIT margin | 15.1 | 12.9 | 12.8 | 12.6 | 12.6 | 12.7 |
| Tax retention ratio | 68.2 | 69.0 | 71.2 | 72.1 | 70.0 | 70.0 |
| Asset turnover (x) | 1.8 | 1.9 | 2.1 | 2.0 | 1.6 | 1.8 |
| ROIC (Post-tax) | 19.0 | 16.6 | 19.0 | 18.0 | 14.2 | 15.8 |
| Cost of Debt (Post Tax) | 8.9 | 10.1 | 8.7 | 7.9 | 7.0 | 7.0 |
| Leverage ( x ) | 0.3 | 0.2 | 0.2 | 0.1 | 0.1 | 0.1 |
| Operating ROE | 22.4 | 18.0 | 20.6 | 19.5 | 15.0 | 16.5 |
| Returns (\%) |  |  |  |  |  |  |
| ROCE (Pre-tax) | 27.3 | 23.8 | 26.4 | 24.7 | 20.1 | 22.3 |
| Angel ROIC (Pre-tax) | 44.1 | 33.7 | 35.9 | 32.4 | 26.8 | 30.3 |
| ROE | 20.6 | 19.5 | 22.7 | 20.5 | 16.5 | 18.0 |
| Turnover ratios (x) |  |  |  |  |  |  |
| Asset Turnover (Gross Block) | 2.7 | 2.6 | 2.8 | 2.7 | 2.3 | 2.5 |
| Inventory / Sales (days) | 72 | 67 | 62 | 74 | 93 | 87 |
| Receivables (days) | 30 | 34 | 35 | 37 | 46 | 44 |
| Payables (days) | 131 | 111 | 98 | 105 | 109 | 95 |
| WC cycle (ex-cash) (days) | 4 | 16 | 20 | 33 | 53 | 51 |
| Solvency ratios (x) |  |  |  |  |  |  |
| Net debt to equity | 0.3 | 0.2 | 0.1 | 0.2 | 0.1 | 0.0 |
| Net debt to EBITDA | 0.8 | 0.7 | 0.3 | 0.5 | 0.2 | 0.1 |
| Interest Coverage (EBIT / Int.) | 10.9 | 9.0 | 17.5 | 22.5 | 18.7 | 25.7 |

## DISCLAIMER

Angel Broking Private Limited (hereinafter referred to as "Angel") is a registered Member of National Stock Exchange of India Limited, Bombay Stock Exchange Limited and Metropolitan Stock Exchange of India Limited. It is also registered as a Depository Participant with CDSL and Portfolio Manager with SEBI. It also has registration with AMFI as a Mutual Fund Distributor. Angel Broking Private Limited is a registered entity with SEBI for Research Analyst in terms of SEBI (Research Analyst) Regulations, 2014 vide registration number INH000000164. Angel or its associates has not been debarred/ suspended by SEBI or any other regulatory authority for accessing /dealing in securities Market. Angel or its associates including its relatives/analyst do not hold any financial interest/beneficial ownership of more than $1 \%$ in the company covered by Analyst. Angel or its associates/analyst has not received any compensation / managed or co-managed public offering of securities of the company covered by Analyst during the past twelve months. Angel/analyst has not served as an officer, director or employee of company covered by Analyst and has not been engaged in market making activity of the company covered by Analyst.

This document is solely for the personal information of the recipient, and must not be singularly used as the basis of any investment decision. Nothing in this document should be construed as investment or financial advice. Each recipient of this document should make such investigations as they deem necessary to arrive at an independent evaluation of an investment in the securities of the companies referred to in this document (including the merits and risks involved), and should consult their own advisors to determine the merits and risks of such an investment.

Reports based on technical and derivative analysis center on studying charts of a stock's price movement, outstanding positions and trading volume, as opposed to focusing on a company's fundamentals and, as such, may not match with a report on a company's fundamentals.

The information in this document has been printed on the basis of publicly available information, internal data and other reliable sources believed to be true, but we do not represent that it is accurate or complete and it should not be relied on as such, as this document is for general guidance only. Angel Broking Pvt. Limited or any of its affiliates/ group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. Angel Broking Pvt. Limited has not independently verified all the information contained within this document. Accordingly, we cannot testify, nor make any representation or warranty, express or implied, to the accuracy, contents or data contained within this document. While Angel Broking Pvt. Limited endeavors to update on a reasonable basis the information discussed in this material, there may be regulatory, compliance, or other reasons that prevent us from doing so.

This document is being supplied to you solely for your information, and its contents, information or data may not be reproduced, redistributed or passed on, directly or indirectly.

Neither Angel Broking Pvt. Limited, nor its directors, employees or affiliates shall be liable for any loss or damage that may arise from or in connection with the use of this information.

Note: Please refer to the important 'Stock Holding Disclosure' report on the Angel website (Research Section). Also, please refer to the latest update on respective stocks for the disclosure status in respect of those stocks. Angel Broking Pvt. Limited and its affiliates may have investment positions in the stocks recommended in this report.

## Disclosure of Interest Statement

## Rallis India

1. Analyst ownership of the stock

No
2. Angel and its Group companies ownership of the stock

No
3. Angel and its Group companies' Directors ownership of the stock

No
4. Broking relationship with company covered

No
Note: We have not considered any Exposure below ₹ 1 lakh for Angel, its Group companies and Directors


[^0]:    Please refer to important disclosures at the end of this report

[^1]:    Source: Company, Angel Research

[^2]:    Source: Company, Angel Research

